Total
0
Shares
Little Green Pharma (ASX:LGP) wins tender to supply medicinal cannabis for national French trial
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Little Green Pharma (LGP) has won a government tender to be a primary supplier of medicinal cannabis oils for a national trial in France
  • The two-year trial will test the efficacy, safety and quality of medicinal cannabis products in up to 3000 patients
  • As part of the trial, LGP will partner with leading pharmaceutical distributor, Intsel Chimos, who will undertake batch-release, distribution, medical information and drug safety obligations
  • Little Green Pharma will be responsible for manufacturing and supplying its medicines into France at its own cost
  • Ultimately, if the trial is successful, it may lead to the legalisation of medicinal cannabis in France — providing LGP with a "first-mover advantage"
  • Company shares are up 11.2 per cent and trading at 64.5 cents

Little Green Pharma (LGP) has been selected as a primary supplier of medicinal cannabis oils for a national trial in France.

Since 2018, the French National Agency for the Safety of Medicines and Health Products has been developing the tender for this two-year trial. The trial is aimed at testing the efficacy, safety and quality of medicinal cannabis products in up to 3000 patients.

These patients will have varying conditions such as refractory neuropathic pain, drug-resistant epilepsy, intractable symptoms linked to cancer or anticancer treatment, palliative situations, or painful spasticity from multiple sclerosis or other issues within the central nervous system.

Ultimately, if the trial is successful, it may lead to the legalisation of medicinal cannabis in France.

The medicinal cannabis trial is in partnership with Intsel Chimos, a leading pharmaceutical distributor and recognised hospital partner in France.

Since 1966, the French company has specialised in importing and distributing medicines to hospitals and dispensaries across France.

Intsel Chimos' role within the partnership involves undertaking batch-release, distribution, medical information and drug safety obligations. Meanwhile, LGP will be responsible for manufacturing and supplying its medicines into France at its own cost.

"We are very proud of our partnership's success in the French national tender and see this tender win as strong evidence of LGP successfully implementing its export-led global sales strategy and demonstrating the benefits of Australian Good Manufacture Practices (GMP) quality manufacturing in global pharmaceutical markets," Little Green Pharma Managing Director Fleta Solomon said.

Fleta also congratulated Intsel Chimos for developing a competitive bid for the tender and is looking forward to working together.

"We trust this marks the beginning of a long and rewarding partnership as we look to grow and cement our reputation amongst French patients and prescribers as a world-class medicinal cannabis supplier," she said.

Significantly, this tender provides Little Green Pharma with a "first-mover advantage" in case medicinal cannabis does end up being legalised in France after the trial.

Company shares are up 11.2 per cent and trading at 64.5 cents at 1:31 pm AEDT.

LGP by the numbers
More From The Market Herald
Creso Pharma (ASX:CPH) - Creso Pharma - The Market Herald

" Creso Pharma (ASX:CPH) launches ecommerce channels, enters Polish markets

Creso Pharma (CPH) has launched new e-commerce channels and expanded into Poland with a maiden purchase order secured.
Emyria (ASX:EMD) contracts consultant for psychedelics and MDMA research

" Emyria (ASX:EMD) contracts consultant for psychedelics and MDMA research

Emyria (EMD) has appointed a consultant to support its psychedelic-assisted therapy programs.
AnteoTech (ASX:ADO) - CEO, Derek Thomson - The Market Herald

" AnteoTech (ASX:ADO) ticks off another distribution deal for EuGeni

AnteoTech (ADO) has signed a distribution agreement with Ramma Dental for its EuGeni Reader platform and SARS-CoV-2 Antigen Rapid Diagnostic Test (RDT).
Healthia (ASX:HLA) - CEO, Wesley Coote - The Market Herald

" Healthia (ASX:HLA) up on Rothwell Physiotherapy buy

Healthia (HLA) shares have enjoyed a 10 per cent rise after reporting a $1.62 million acquisition of Queensland’s Rothwell Physiotherapy.